UCB launches Wear It Out: what it means for UCB stock

Published on 10/17/2026 at 10:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UCB outlined Wear It Out on October 13, 2026 with patient advocates. What it means for UCB stock is a program built around three immune conditions.

Patient program and next session

On October 13, 2026, UCB announced the Wear It Out program with patient advocates.
The next Xetra session is scheduled for October 19, 2026.
UCB's investor page was last updated October 16, 2026.

Isometrische 3D-Illustration einer Wertschöpfungskette von Labor über Produktion bis zum Krankenhaus — UCB S.A. mit ISIN BE0003739530 dargestellt als isometrisches 3D-Diagramm der biopharmazeutischen Wertschöpfungskette, Illustration mit AI erstellt.

UCB announced the launch of Wear It Out on October 13, 2026, a program developed with patient advocates for people living with hidradenitis suppurativa, plaque psoriasis and psoriatic arthritis, according to PR Newswire.

The initiative uses patient stories and designs created with artist Sophia Yeshi to highlight everyday decisions and compromises associated with the three conditions. UCB said participants can join the community, access resources and share their stories through the program.

UCB is listed on Euronext Brussels under the symbol UCB. Its investor-relations page identifies the company as a biopharmaceutical company focused on neurological and immunological diseases and was last updated October 16, 2026.

Market context: Market report Euro Stoxx 50.